DOJ settlement requires Cleveland Clinic to fund and promote detransition services

The Department of Justice announced a settlement with Cleveland Clinic following a federal investigation into the clinic’s treatment practices for patients who received gender-affirming care as minors. The agreement, announced Friday, requires Cleveland Clinic to provide detransition services for eligible patients and to set aside funds for care connected to detransition, according to DOJ’s announcement reported by The Hill.

Under the terms described in reporting on the deal, Cleveland Clinic will make available detransition services to patients regardless of their ability to pay. The settlement also includes publicity and outreach requirements, including a dedicated website, a phone number, assignment of a care coordinator, and direct outreach to organizations that provide non-medical services to people seeking detransition, as characterized in The Hill’s account of a copy of the settlement.

The monetary component described by The Hill is a $2 million pledge tied to detransition care. Reporting further says the agreement specifies that detransition services can include medical care for hormonal balancing, surgical revision and reconstruction, fertility restoration, psychological support including grief counseling, and insurance coordination for individuals seeking detransition.

Several local and medical-coverage reports also describe additional limitations on Cleveland Clinic’s provision of gender-related medical care to minors as part of the settlement. WKYC and reported that the clinic agreed to a multi-decade halt on certain gender-affirming medical treatments for minors, with timeframes of roughly two decades described in those accounts.

The DOJ settlement marks what multiple reports describe as a second major health-system agreement involving federal scrutiny of gender-affirming care, after another large hospital’s earlier settlement under the same DOJ approach. The settlement’s implementation is expected to involve operational steps within the health system, including establishing the required points of contact and care navigation described in the reported agreement.

The Cleveland Clinic has not been represented by official primary language in the material provided for this write-up beyond the DOJ terms as summarized by reporting. Public reaction is also mixed in coverage: advocates for transgender Ohioans criticized the agreement, while other supporters and critics of the policy dispute the medical and ethical framing of detransition services, reflecting ongoing national disagreement over how such care should be regulated and reimbursed.

The settlement does not resolve broader litigation or policy disputes cited in coverage about gender-affirming care generally, but it does create binding obligations for Cleveland Clinic within the settlement’s scope and timeline. Next steps for patients and providers will likely center on how the system routes requests for detransition services, how it publicizes access, and how it defines eligibility under the agreement described in the reporting.